

Attorney Docket No. 5579.210-US



RECEIVED  
PATENT & TRADEMARK OFFICE  
TECH CENTER 1600/2900  
SEP 13 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jesper Vind

Confirmation No: 1334

Serial No.: 09/426,038

Group Art Unit: 1627

Filed: October 25, 1999

Examiner: P. Ponnaluri

For: Methods Of Constructing And Screening A DNA Library Of Interest In Filamentous Fungal Cells

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Commissioner for Patents  
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:


1. Amendment Fee Transmittal (in duplicate)
2. Amendment and Marked Up Version pursuant to 37 C.F.R. 1.21

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
Washington, DC 20231

on September 4, 2001.

Kelley O'Patry  
(name of person mailing paper)

  
(signature of person mailing paper)



Attorney Docket No.: 5579.210-US

**RECEIVED**  
SEP 13 2001  
FEDERAL BUREAU OF INVESTIGATION  
U.S. DEPARTMENT OF JUSTICE  
1600/2900

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Jesper Vind

Confirmation No: 1334

Serial No.: 09/426,038

Group Art Unit: 1627

Filed: October 25, 1999

Examiner: P. Ponnaluri

For: Methods Of Constructing And Screening A DNA Library Of Interest In Filamentous Fungal Cells

## AMENDMENT FEE TRANSMITTAL

Commissioner for Patents  
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-identified application in response to the Office Action mailed March 1, 2001.

It is respectfully requested that the time for response to the Office Action dated March 1, 2001 be extended for a period of 3 months from June 1, 2001 to September 1, 2001. The required fee for the extension is estimated to be \$890.

Please charge the required extension fee, estimated to be \$890, as well as any other fees due and owing, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: September 4, 2001

~~Jason I. Garbell, Reg. No. 44,116  
Novozymes North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123~~



Attorney Docket No.: 5579.210-US

RECEIVED  
TECH CENTER 1600/2900  
SEP 13 2001  
P A T E N T & T R A D E M A R K O F F I C E  
9/18/01  
A. Harmon

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Jesper Vind Confirmation No: 1334

Serial No.: 09/426,038 Group Art Unit: 1627

Filed: October 25, 1999 Examiner: P. Ponnaluri

For: Methods Of Constructing And Screening A DNA Library Of Interest In Filamentous Fungal Cells

**AMENDMENT UNDER 37 C.F.R. 1.111**

09/11/2001 BABRAKA1 00000073 501701 09426038

Commissioner for Patents  
Washington, DC 20231

01 FC:117 890.00 CH

Sir:

In response to the Office Action mailed March 1, 2001, please amend the above-identified application as follows (a marked up version pursuant to 37 C.F.R. 1.21 is attached hereto):

**IN THE SPECIFICATION:**

Please delete the cross-reference to related applications section on page 1, and replace with the following:

**--CROSS-REFERENCE TO RELATED APPLICATION**

*(B)*  
This application is a continuation-in-part of U.S. Pat. Application Serial No. 09/186,665, now abandoned, and claims priority under 35 USC 119 of Danish applications no. PA 1998 01375, filed October 26, 1998, and PA 1999 00718, filed May 25, 1999, the contents of which are fully incorporated herein by reference.--

Please replace the paragraph on page 1, line 27 to page 2, line 3 with:

*(B2)*  
--Often, however, a polynucleotide sequence identified by screening in yeast or bacteria cannot be expressed or is expressed at low levels when transformed into production relevant filamentous fungal cells. This may be due to any number of reasons, including differences in codon usage, regulation of mRNA levels, translocation apparatus, post-translational modification